People · Operator
Named in public records as an officer, director or promoter · active 2014–2014 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | — | Biotechnology | Series C | $73.2M | $2.0B | 2014 |
Christoph S. Lengauer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christoph S. Lengauer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Alexis Borisy | 1 | 6 |
| Daniel S. Lynch | 1 | 6 |
| Kyle Kuvalanka | 1 | 3 |
| Jeffrey W. Albers | 1 | 2 |
| Stephen S. Knight | 1 | 1 |
| Thilo S. Schroeder | 1 | 1 |
| David S. Schenkein | 1 | 1 |
| Christine W. Bellon | 1 | 1 |
| Nick S. Lydon | 1 | 1 |
| Christine Bellon | 1 | 1 |
| Alexis S. Borisy | 1 | 1 |
| Nicholas S. Lydon | 1 | 1 |
| Kyle W. Kuvalanka | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.